Candel Therapeutics Inc (CADL) Directors and Executive Officers

Officers & Directors

Candel Therapeutics Inc. Executives and Directors:

- Paul B. Manning, Chairman
- Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer (Principal Executive Officer)
- Charles Schoch, Interim Chief Financial Officer (Principal Financial and Accounting Officer)
- Edward J. Benz Jr., Director
- Diem Nguyen, Director
- Nicoletta Loggia, Director
- Renee Gaeta, Director
- Gary Nabel, Director
- Estuardo Aguilar-Cordova, Director
- Joseph Papa, Director
- Chris Martell, Director

Auditor:
- (auditor since - ),

Candel Therapeutics Inc currently has 55 employees.

News about Candel Therapeutics Inc Key Personnel

Candel Therapeutics Taps Pancreatic Cancer Authority Elizabeth Jaffee Amid Financial Struggles: Searching for Breakthroughs in a Challenging Landscape,

Candel Therapeutics Appoints Pancreatic Cancer Expert Amid Struggles: A New Chapter or an Uphill Battle?NEEDHAM, Mass.—In a move that signals both promise and urgency, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company, has appointed Dr. Elizabeth M. Jaffee, an internationally renowned expert in cancer immunology and pancreatic cancer, to its Research Advisory Board (RAB). This decision comes at a pivotal time for the company, which is focused on developing cutting-edge immunotherapies to combat one of the deadliest forms of cancer—borderline resectable pancreatic cancer.Dr. Jaffee s expertise will be crucial as Candel couples its ambitious plans with the harsh reality ...

Candel Therapeutics Defies Financial Headwinds, Joins Russell 3000 Index

Candel Therapeutics Joins Russell 3000 Index, Despite Cumulative Net Loss
Candel Therapeutics, a clinical stage biopharmaceutical company focused on cancer immunotherapies, has announced its inclusion in the broad-market Russell 3000 Index. The decision was made during the 2024 Russell US Indexes annual reconstitution, with the company set to join the index at the open of US equity markets on July 1, 2024. This development was based on a preliminary list of additions published on May 24, 2024.
Despite its achievement, Candel Therapeutics Inc has experienced a cumulative net loss of $-32 million in the 12-month period ending in the third quarter of 2023. This has resulted in a negative return on inve...